Core Insights - The release of the 2025 National Medical Insurance Drug List and the first version of the Commercial Health Insurance Innovative Drug List has significantly benefited innovative drug companies on the Sci-Tech Innovation Board [1] - A total of 9 innovative drugs from Sci-Tech Innovation Board companies have been included in the new list, showcasing their strong capabilities [1] - The simultaneous release of the commercial insurance drug list marks a substantial breakthrough in the multi-layered payment system of "medical insurance + commercial insurance" [1] Group 1: Inclusion in Medical Insurance - Nearly 90% of innovative drugs from Sci-Tech Innovation Board companies have received medical insurance support, accelerating their value release and development [2] - Junshi Bioscience's drug, Junsida, is the only domestic PCSK9-targeted drug for statin-intolerant patients included in the new medical insurance list [2] - Haichuang Pharmaceutical's drug, Hainaan, has been approved for treating metastatic castration-resistant prostate cancer and will enhance market promotion and patient accessibility [2] Group 2: New Drug Development - New anti-tumor drugs from companies like Ailis, Yifang Biotech, and Shenzhou Cell provide precise treatment options for major diseases such as lung cancer and head and neck squamous cell carcinoma [3] - Several drugs covering endocrine, hematology, tumor support, and autoimmune treatment areas have been quickly included in the medical insurance list, demonstrating efficient drug review and approval processes [3] Group 3: Commercial Health Insurance Directory - The first version of the Commercial Health Insurance Innovative Drug List enhances the national multi-layered medical security system, with a clear division of roles between basic medical insurance and commercial insurance [4] - Innovative drugs from leading companies like BeiGene have been among the first to be included in this new directory, showcasing their clinical value [4][5] Group 4: Renewal and Market Expansion - Successful renewal negotiations confirm the exceptional value and clinical status of innovative drugs from Sci-Tech Innovation Board companies [6] - Junshi Bioscience's drug, Tuoyi, has expanded its medical insurance coverage with new indications, benefiting a broader patient population [6] Group 5: R&D Investment and Innovation Cycle - R&D investment among Sci-Tech Innovation Board companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42% [7] - The formation of a virtuous cycle of "R&D investment - innovation results - medical/commercial insurance support - market returns - reinvestment in R&D" is evident in the industry [7]

Group 1 - Haichuang Pharmaceutical increased by over 10% [1] - Frontier Biotech rose by over 8% [1] - Yuekang Pharmaceutical, Rejing Biotech, Huisheng Biotech, and Zhongsheng Pharmaceutical also experienced gains [1]

Core Insights - On December 10, 2023, brokerage firms provided target prices for listed companies, with significant increases noted for Yilian Network, Xingfu Electronics, and Yingke Recycling, showing target price increases of 53.21%, 40.35%, and 35.77% respectively, across the communication equipment, electronic chemicals, and plastics industries [1][2]. Group 1: Target Price Increases - Yilian Network received a target price of 53.50 yuan, reflecting a target price increase of 53.21% [2]. - Xingfu Electronics was assigned a target price of 52.00 yuan, with a target price increase of 40.35% [2]. - Yingke Recycling's target price is set at 40.04 yuan, indicating a target price increase of 35.77% [2]. - Guizhou Tire, with a target price of 6.60 yuan, shows a target price increase of 29.92% [2]. - Guki Wool Material has a target price of 33.00 yuan, reflecting a target price increase of 23.32% [2]. Group 2: Rating Adjustments - Three companies had their ratings upgraded on December 10, including Yingke Recycling, which was upgraded from "Hold" to "Buy" by Huatai Securities [3][4]. - Tian Nai Technology's rating was raised from "Hold" to "Outperform" by Guosen Securities [3][4]. - Haiguang Information's rating was upgraded from "Range Trading" to "Buy" by Qunyi Securities (Hong Kong) [3][4]. Group 3: First-Time Coverage - Eight companies received initial coverage from brokerages on December 10, including Guizhou Tire, which was rated "Buy" by Global Fortune Financial [5][6]. - Fusheng Technology received an "Increase" rating from China Merchants Securities [5][6]. - Kaizhong Co. was rated "Increase" by Northeast Securities [5][6]. - Hand Information was rated "Buy" by CITIC Construction Investment Securities [5][6]. - Guki Wool Material was rated "Increase" by Tianfeng Securities [5][6].

Market Overview - The A-share market showed mixed performance on December 9, with the Shanghai Composite Index down 0.13% at 3918.83 points, while the Shenzhen Component rose 0.09% and the ChiNext Index increased by 1.07% [2] - The total trading volume in the Shanghai and Shenzhen markets was 1.26 trillion yuan, a decrease of 34.7 billion yuan compared to the previous trading day, with 1738 stocks rising and 3555 stocks falling [4] Sector Performance - The optical module (CPO) sector continued to rise, along with innovative pharmaceuticals, consumer electronics, and retail stocks, while precious metals and real estate sectors lagged [5] - The CPO concept achieved a four-day consecutive rise, with stocks like Zhongji Xuchuang and Tianfu Communication reaching new highs [10] - The innovative pharmaceutical sector was active, with Hai Chuang Pharmaceutical rising over 13% and Zhao Yan New Drug increasing over 8% [18] - The consumer electronics sector saw significant activity, with stocks like Dahua Intelligent and Furuon Technology hitting the daily limit [22] - The commercial retail sector experienced a strong surge, with multiple stocks such as Central Plaza and Yonghui Supermarket reaching the daily limit [27] Notable Stocks - Zhongji Xuchuang rose by 6.94% to 609.58 yuan per share, with a market capitalization of 677.3 billion yuan [11] - Hai Chuang Pharmaceutical reached 53.75 yuan per share, up 13.13%, with a market capitalization of 5.3 billion yuan [19] - Dahua Intelligent recorded a 9.96% increase to 7.84 yuan per share, with a market capitalization of 8.7 billion yuan [24] - Central Plaza saw a 10.03% rise to 4.06 yuan per share, with a market capitalization of 4.6 billion yuan [28] News Impact - The National Medical Insurance Drug List for 2025 was released, adding 114 new drugs, with a success rate of 88%, significantly higher than the previous year's 76% [20] - Google's recent launch of the AndroidXR-themed smart glasses in collaboration with XREAL is expected to impact the consumer electronics market [25] - The U.S. government announced that NVIDIA would be allowed to sell its H200 AI chips to China, which may influence the semiconductor sector [34]

板块上来看，创新药概念股表现活跃，CPO、电子元器件、互联网等板块涨幅居前；而贵金属、海南自贸港、房地产等震荡调整。 一起来看下最新的市场情况及资讯。 12月9日开盘，A股市场震荡拉升，创业板指涨逾1%，沪指跌0.03%，深成指涨0.35%。 | 上证指数 | 深证成指 | 北证50 | | --- | --- | --- | | 3922.79 | 13376.53 | 1418.57 | | -1.28 -0.03% | +46.54 +0.35% | -7.68 -0.54% | | 科创50 | 创业板指 | 万得全A | | 1353.91 | 3224.50 | 6322.00 | | +3.12 +0.23% | +34.23 +1.07% | +6.53 +0.10% | | 沪深300 | 中证500 | 中证A500 | | 4624.80 | 7179.66 | 5564.18 | | +3.05 +0.07% | +7.29 +0.10% | +2.81 +0.05% | | 中证1000 | 深证100 | 中证红利 | | 7437.69 | 5895.60 | 5502.05 | ...

Group 1 - The core viewpoint of the article highlights that Haichuang Pharmaceutical (SH 688302) held its 15th meeting of the second board on December 8, 2025, to discuss amendments to the company's articles of association [1] - For the first half of 2025, Haichuang Pharmaceutical's revenue composition was 99.25% from pharmaceuticals and 0.75% from materials and R&D intermediates [1] - As of the report, Haichuang Pharmaceutical has a market capitalization of 4.7 billion yuan [1] Group 2 - The article also discusses the emergence of addiction cases related to the misuse of pregabalin in China, marking the first report of such incidents [1] - It mentions that online platforms have exposed vulnerabilities in purchasing medications without medical records, raising concerns about regulatory oversight [1] - The classification of pregabalin and the need for scientific evaluation regarding its regulation are emphasized [1]

海创药业股份有限公司 章程 二零二五年十二月 | 第一章 | 总则 - | 1 - | | --- | --- | --- | | 第二章 | 经营宗旨和范围 - | 2 - | | 第三章 | 股份 - | 2 - | | 第一节 | 股份发行 | - 3 - | | 第二节 | 股份增减和回购 | - 6 - | | 第三节 | 股份转让 | - 7 - | | 第四章 | 股东和股东会 - | 8 - | | 第一节 | 股东的一般规定 | - 8 - | | 第二节 | 控股股东和实际控制人 - | 10 - | | 第三节 | 股东会的一般规定 - | 11 - | | 第四节 | 股东会的召集 - | 14 - | | 第五节 | 股东会的提案与通知 - | 16 - | | 第六节 | 股东会的召开 - | 17 - | | 第七节 | 股东会的表决和决议 - | 20 - | | 第五章 | 董事和董事会 - | 23 - | | 第一节 | 董事的一般规定 - | 24 - | | 第二节 | 董事会 - | 27 - | | 第三节 | 独立董事 - | 30 - | | 第四节 | 董事 ...

鉴于公司实际情况及经营发展需要，将对公司的住所进行如下变更： 一、变更公司住所的情况 变更前：四川省成都市高新区科园南路 5 号蓉药大厦 1 栋 4 层附 2、3 号。 变更后：四川省成都市双流区凤凰路 558 号。 证券代码：688302 证券简称：海创药业 公告编号：2025-053 海创药业股份有限公司 关于修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 海创药业股份有限公司(以下简称"公司")于 2025 年 12 月 8 日召开第二届 董事会第十五次会议，审议通过了《关于修订<公司章程>的议案》，现将具体情 况公告如下: 董事会 2025 年 12 月 9 日 二、修订《公司章程》情况 鉴于公司上述变更的情况，根据相关法律法规要求，拟修改《公司章程》相 应条款，具体如下： | 修订前 | 修订后 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 第五条 | 公司住所：四川省成都市高新区科园南路 | ...

证券代码：688302 证券简称：海创药业 公告编号：2025-054 海创药业股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一） 股东会类型和届次 2025年第二次临时股东会 召开日期时间：2025 年 12 月 24 日 14 点 00 分 召开地点：四川省成都市高新区科园南路 5 号蓉药大厦 1 栋 4 层公司会议 室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 24 日 至2025 年 12 月 24 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 重要内容提示： 一、 召开会议的基本情况 股东会召开日期：2025年12月24日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 东 ...

证券代码：688302 证券简称：海创药业 公告编号：2025-052 海创药业股份有限公司 第二届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 海创药业股份有限公司（以下简称"公司"）第二届董事会第十五次会议于2025 年12月8日在公司会议室以通讯表决方式召开，会议通知已于2025年12月1日以电子邮 件等形式送达全体董事。本次会议应到董事7名，实到董事7名，会议由董事长YUANWEI CHEN（陈元伟）先生主持。本次会议的召集、召开、议案审议程序符合《中华人民共 和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公司章程》的有关 规定，会议决议合法、有效。 经审议，董事会同意《关于提请召开2025年第二次临时股东会的议案》。 表决结果：同意7票，反对0票，弃权0票。 具体内容详见公司披露于上海证券交易所网站(www.sse.com.cn)的《海创药业股 份有限公司关于召开2025年第二次临时股东会的通知》。 特此公告。 二、董事会会议审议情况 全体董事对本 ...